640 articles
Tenecteplase
Tenecteplase (TNKase, Metalyse) is a modified recombinant tissue plasminogen activator thrombolytic, approved in 2000 for STEMI, given as a single bolus, with 14-fold higher fibrin specificity than alteplase.
Teneligliptin
Teneligliptin (Tenelia, MP-513) is an oral DPP-4 inhibitor by Mitsubishi Tanabe Pharma for type 2 diabetes, first approved in Japan in 2012, dosed 20-40 mg once daily, with no dose adjustment needed in renal or hepatic impairment.
Tertatolol
Tertatolol (S 2395, Artex) is a Servier-developed nonselective beta-blocker without intrinsic sympathomimetic activity, ATC C07AA16, dosed 5 mg once daily for hypertension, with renal vasodilating and 5-HT1A antagonist properties; French marketing ended 2023.
Terutroban
Terutroban (S 18886, Triplion) is Servier's oral, reversible thromboxane-prostaglandin (TP) receptor antagonist antiplatelet drug; development stopped after the 19,120-patient PERFORM trial failed noninferiority versus aspirin.
Tesaglitazar
Tesaglitazar (Galida, AZ-242), an AstraZeneca dual PPARα/γ agonist for type 2 diabetes, lowered glucose and triglycerides in trials but was discontinued in May 2006 over creatinine and GFR effects.
Tesamorelin
Tesamorelin (Egrifta, TH9507) is a synthetic 44-amino-acid GHRH analogue, FDA approved in 2010 to reduce excess abdominal fat in HIV-infected adults with lipodystrophy; it lowers visceral fat about 15-20% and raises IGF-1, with edema, arthralgia, and glucose intolerance as risks.
Testosterone replacement therapy
Testosterone replacement therapy (TRT) is the medical administration of testosterone, usually as a gel, injection, patch, or pellet, to restore normal hormone levels in men with hypogonadism.
Tetradecyl sulfuric acid
Tetradecyl sulfuric acid, as sodium tetradecyl sulfate (STS, Sotradecol), is a detergent sclerosant introduced by Leopold Reiner in 1946, FDA approved for varicose veins, used in liquid or foam sclerotherapy and compared with polidocanol.
Tezosentan
Tezosentan (Ro 61-0612) is an intravenous, short-acting dual endothelin ETA/ETB receptor antagonist developed by Actelion as a vasodilator for acute heart failure; RITZ and VERITAS trials showed hemodynamic effects but no clinical benefit, and development was discontinued.
TG103
TG103 (依达格鲁肽α) is a once-weekly GLP-1/Fc fusion protein injection by CSPC Baike for type 2 diabetes and obesity; phase 3 trials completed in China, CDE filing accepted.
Thiazide
Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide) block the sodium-chloride cotransporter in the distal convoluted tubule; first-line hypertension drugs since chlorothiazide's 1958 launch, also used for kidney stones and edema.
Thyrotropin alfa
Thyrotropin alfa (Thyrogen, rhTSH) is a recombinant human thyroid-stimulating hormone injected intramuscularly to detect and ablate thyroid remnants after thyroidectomy for well-differentiated thyroid cancer.
Ticrynafen
Ticrynafen (tienilic acid, Selacryn, SKF 62698) is a withdrawn uricosuric diuretic antihypertensive approved in the US in 1979, distinguished by lowering serum uric acid, and withdrawn January 1980 for immunoallergic hepatitis linked to anti-LKM2 antibodies against CYP2C9.
Tigulixostat
Tigulixostat, also known by the development code LC350189, is a once-daily, selective xanthine oxidase inhibitor from LG Chem for lowering serum urate in gout, now in Phase 3 trials.
Tiludronic acid
Tiludronic acid (tiludronate, SR 41319, Skelid, Tildren) is a first-generation non-nitrogen bisphosphonate inhibiting osteoclasts, FDA-approved in 1997 for Paget's disease and used intravenously for navicular syndrome in horses.
Tinzaparin sodium
Tinzaparin sodium (Innohep) is a porcine low-molecular-weight heparin made by heparinase depolymerization, mean MW about 6,500 Da, dosed 175 anti-Xa IU/kg once daily for DVT, PE, cancer-associated VTE, and hemodialysis circuits; FDA approved 2000.
Tiratricol
Tiratricol (Triac, Emcitate), a T3 thyroid hormone analogue that enters cells without the MCT8 transporter; first approved treatment for peripheral thyrotoxicosis in MCT8 deficiency (Allan-Herndon-Dudley syndrome), EU 2025, US 2026.
Tisopurine
Tisopurine (thiopurinol, Exuracid, NSC-1392), C5H4N4S, CAS 5334-23-6, ATC M04AA02, is the 4-thio analog of allopurinol, an approved antigout drug that lowers uric acid by interfering with early urate synthesis rather than xanthine oxidase inhibition.
Tocainide
Tocainide (Tonocard) is an orally active class IB antiarrhythmic lidocaine analog, FDA-approved 1984 for ventricular arrhythmias, later discontinued in the US; also trialed for neuropathic pain.
Tofogliflozin anhydrous
Tofogliflozin anhydrous is the anhydrous form of tofogliflozin, a highly selective SGLT2 inhibitor approved in Japan in 2014 for adults with type 2 diabetes, sold as DEBERZA and Apleway.
Tolazamide
Tolazamide (Tolinase) is a first-generation sulfonylurea oral drug for type 2 diabetes, FDA approved July 1966, about 5-6 times as potent as tolbutamide, no longer available in the United States.
Tolrestat
Tolrestat (Alredase, AY-27,773), an aldose reductase inhibitor for diabetic neuropathy, approved 1988, showed modest nerve-function benefit in trials, and was withdrawn worldwide in 1996 after fatal hepatic necrosis.
Tonapofylline
Tonapofylline (BG-9928) is a xanthine adenosine A1 receptor antagonist developed by Biogen Idec for heart failure and kidney disease; trialed in TRIDENT-1 and POSEIDON but abandoned for lack of efficacy.
Torsemide
Torsemide (torasemide), a loop diuretic approved in the US in 1993, inhibits Na+/K+/2Cl− in the loop of Henle to treat edema from heart failure, renal, or hepatic disease and hypertension; roughly twice as potent as furosemide, but TRANSFORM-HF showed no outcome difference.
TRC4186
TRC4186 (also written TRC-4186) is a pyridinium advanced glycation end-product (AGE) cross-link breaker from Torrent Pharmaceuticals, India, tested for diabetic cardiomyopathy and heart failure; its Phase II trial ended early on safety grounds.
Trelagliptin
Trelagliptin (SYR-472, Zafatek) is a once-weekly oral DPP-4 inhibitor for type 2 diabetes, approved in Japan in March 2015 as the first once-weekly oral antidiabetic; 100 mg weekly, non-inferior to daily alogliptin.
Treprostinil
Treprostinil is a stable prostacyclin analogue for pulmonary arterial hypertension and PH-ILD, given orally, subcutaneously, intravenously, or inhaled; first FDA-approved 2002 (Remodulin), with Yutrepia inhalation powder approved May 2025.
Tricaprilin
Tricaprilin (AC-1202, CER-0001, glyceryl tricaprylate) is an 8-carbon medium-chain triglyceride ketogenic agent studied for mild to moderate Alzheimer's disease, marketed as Axona, with benefit mainly in APOE4-negative patients.
Trichlormethiazide
Trichlormethiazide (Naqua, Metahydrin) is an oral thiazide diuretic similar to hydrochlorothiazide, C8H8Cl3N3O4S2, ATC C03AA06, dosed 2–4 mg daily for edema and hypertension; first approved 1960, discontinued in the US.
Triflusal
Triflusal, marketed as Disgren, is an oral antiplatelet drug related to the salicylates, used to prevent recurrent stroke and myocardial infarction in Europe and South Korea.